Loading...
01/11 13:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call suggests a positive outlook with strong financial metrics, ongoing product development, and strategic cost-cutting measures. The company is optimistic about its pipeline and regulatory interactions, despite some uncertainties in demand. The focus on partnerships and expansion in oncology and vaccines indicates growth potential. No significant negative trends were highlighted, and management's cautious optimism suggests a positive sentiment. However, the lack of specific guidance on some aspects prevents a stronger positive rating.
Revenue $2.1 billion in Q2 2025, reflecting a highly seasonal nature of the respiratory vaccine business. This is a decline of 38% year-over-year, primarily due to lower COVID vaccine sales.
Net Loss $0.8 billion in Q2 2025, an improvement of $454 million compared to a $1.3 billion loss in Q2 2024. Loss per share improved from $3.33 in 2024 to $2.13 in 2025.
Cash and Investments $7.5 billion at the end of Q2 2025, down from $8.4 billion at the end of Q1 2025, primarily driven by the operating loss for the quarter.
Cost of Sales $119 million in Q2 2025, relatively flat compared to $115 million in Q2 2024. However, it represented 105% of net product sales this quarter, up from 62% in the prior year, driven primarily by lower volume.
R&D Expenses $700 million in Q2 2025, down 43% year-over-year. The decline was primarily driven by the wind-down of respiratory trials and lower clinical manufacturing costs.
SG&A Expenses $230 million in Q2 2025, down 14% year-over-year. The decrease reflects broad-based cost reductions across external services, personnel, and commercial activities.
Net Product Sales $114 million in Q2 2025, primarily driven by COVID vaccine sales. This is a decline of 38% compared to Q2 2024, but slightly above expectations due to a stronger-than-expected U.S. spring booster season.
mNEXSPIKE approval: FDA approved mNEXSPIKE, a next-generation COVID vaccine with higher efficacy than prior Spikevax vaccine.
mRESVIA approval: FDA approved mRESVIA vaccine for high-risk individuals aged 18-59, expanding its use beyond adults 60+.
Spikevax pediatric approval: FDA granted full approval for Spikevax COVID vaccine for high-risk children aged 6 months to 11 years.
Flu vaccine efficacy: Positive Phase III efficacy data for flu vaccine, showing 26.6% higher efficacy than standard dose comparator.
Geographic expansion: Spikevax received EMA approval for updated strain in Europe; mRESVIA approved in 38 countries.
U.K. contract update: Timing shift of U.K. COVID vaccine shipments from 2025 to 2026 due to fiscal year adjustments.
Cost reductions: Achieved 35% reduction in cost of sales and SG&A combined year-over-year; reduced operating expenses by $581 million in Q2 2025.
Workforce restructuring: Announced 10% workforce reduction to align cost structure with business conditions.
AI integration: 100% of knowledge workers actively use AI tools like ChatGPT daily, enhancing operational efficiency.
Pipeline prioritization: Focused on late-stage pipeline with potential for 10 product approvals targeting a $30 billion market.
Oncology advancements: Progress in oncology portfolio, including Phase III trials for intismeran and other cancer therapies.
Seasonal nature of respiratory vaccine business: The company's revenue is highly dependent on the seasonal demand for respiratory vaccines, which could lead to fluctuations in financial performance.
Decline in product sales: Net product sales declined by 38% compared to the same quarter in the previous year, reflecting challenges in maintaining consistent sales levels.
Competitive market pressures: The company faces uncertainties in vaccination rates and competitive pressures in the market, which could impact revenue.
Supply chain timing issues: A $300 million revenue reduction was attributed to a timing shift in U.K. COVID vaccine shipments, highlighting potential supply chain and delivery challenges.
Workforce reduction: The company announced a 10% workforce reduction to align costs with business conditions, which could impact employee morale and operational capacity.
High cost of sales: Cost of sales represented 105% of net product sales this quarter, up from 62% in the prior year, driven by lower volume and increased costs.
Dependence on regulatory approvals: Future revenue is dependent on the timing of regulatory approvals for products in various countries, which introduces uncertainty.
Economic uncertainties: The company is exposed to economic uncertainties, including changes in global tariffs and vaccination rates, which could affect financial performance.
Patent litigation: The company is involved in ongoing patent litigation with Pfizer and BioNTech, which could result in legal costs and potential reputational risks.
R&D cost reductions: While reducing R&D expenses to manage costs, there is a risk that this could impact the pace of innovation and future product development.
Revenue Projections: Moderna updated its 2025 projected revenue range to $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end due to a timing shift of U.K. COVID shipments to Q1 2026. U.S. product sales are expected to range from $1.0 billion to $1.5 billion, while international product sales are projected at $0.4 billion to $0.6 billion. Other revenues are estimated at approximately $100 million.
Cost and Expense Reductions: The company plans to reduce annual GAAP operating expenses from $11 billion in 2023 to $5 billion or less in 2027. For 2025, operating expenses are projected at $5.9 billion to $6.1 billion, with a cash cost target of $5.1 billion. Key drivers include reductions in R&D expenses, manufacturing efficiencies, procurement savings, and a 10% workforce reduction.
Capital Expenditures: Capital expenditures for 2025 have been lowered from $400 million to $300 million due to prioritization and efficiency gains.
Pipeline and Product Approvals: Moderna aims to deliver up to 10 product approvals by 2028, targeting an addressable market of over $30 billion. Approvals for mNEXSPIKE, mRESVIA, and pediatric Spikevax have been secured in 2025. Seasonal flu and flu-COVID combination vaccines are expected to gain approval based on positive Phase III data.
Oncology and Rare Diseases: The company is advancing its oncology portfolio with several late-stage trials, including intismeran in adjuvant melanoma and other cancers. Rare disease programs for propionic acidemia and methylmalonic acidemia are progressing, with potential approvals targeted for 2027.
AI Integration: Moderna has integrated AI tools across its operations, enhancing efficiency in areas like product planning and research. The company plans to continue leveraging AI to improve business processes and reduce costs.
The selected topic was not discussed during the call.
The earnings call summary and Q&A reveal concerns about declining vaccination rates, reduced revenue projections, and unclear guidance on future large deals. Despite cost reduction plans and strategic partnerships, the market may react negatively to the reduced revenue guidance and lack of detailed future growth projections. The negative sentiment is reinforced by declining COVID vaccine demand and the cautious outlook on new product launches. These factors suggest a likely negative stock price movement in the short term.
The earnings call suggests a positive outlook with strong financial metrics, ongoing product development, and strategic cost-cutting measures. The company is optimistic about its pipeline and regulatory interactions, despite some uncertainties in demand. The focus on partnerships and expansion in oncology and vaccines indicates growth potential. No significant negative trends were highlighted, and management's cautious optimism suggests a positive sentiment. However, the lack of specific guidance on some aspects prevents a stronger positive rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
